Eli Lilly will report third-quarter 2026 financial results on October 29, with its conference call scheduled to begin at 10 a.m. Eastern time. The update will test whether rapid demand for Mounjaro and Zepbound continues to outweigh lower realized pricing and heavy investment in manufacturing and research.

The Date and Baseline

Lilly confirmed the October 29 event on October 15. The reporting date is therefore separate from the announcement date, an important distinction for investors planning around the catalyst.

The baseline is unusually strong. In its August 5 second-quarter release, Lilly reported revenue of $22.974 billion, up 48% from a year earlier. Reported earnings per share increased 26% to $7.94, while non-GAAP EPS rose 33% to $8.38. The company raised full-year revenue guidance to $85 billion to $87 billion and set non-GAAP EPS guidance at $35.50 to $36.50.

Mounjaro and Zepbound Face a Pricing Test

Volume was the main engine in the second quarter, increasing 60%, but lower realized prices reduced revenue growth by 13 percentage points. That mix makes product demand only half the earnings story. Investors also need to assess rebates, discounts, geographic expansion and whether newer manufacturing capacity is improving supply.

Mounjaro and Zepbound remain the central products to watch, but the pipeline and spending profile also matter. Lilly said it committed another $4.5 billion to expand manufacturing sites in Indiana and continued investing in late-stage programs. Readers can compare the drug-demand setup with Fusion Market News’ Regeneron earnings preview and ANI Pharmaceuticals earnings preview.

Guidance, Margins and Pipeline Signals

The clearest market-moving question is whether Lilly changes its $85 billion to $87 billion revenue range. A guidance increase would signal confidence in demand and supply execution, while unchanged guidance could still be constructive if margins and cash generation remain strong.

Investors should also watch gross margin, research spending and management’s timing for key pipeline filings. Lilly previously said the clinical package for retatrutide in obesity was complete and planned a U.S. submission in the first quarter of 2027. The balance between current product growth and future investment will shape the quality of the quarter. For a separate view of how markets evaluate growth investment, see Fusion Market News’ AMD earnings preview.

Elsy Kanana is a financial and cryptocurrency journalist at FusionMarketNews, covering digital assets, blockchain technology, financial markets, and emerging fintech trends. Her reporting focuses on market movements, regulatory developments, and on-chain analytics, delivering clear, data-driven insights to readers worldwide.